title: Outcomes of hemodiafiltration based on Japanese dialysis patient registry.
abstract: Effectiveness of various therapeutic modalities was analyzed among 1,196 patients entered in the registry of the Japanese Society for Dialysis Therapy who were on hemopurification therapy as of the end of 1998 and developed dialysis-related amyloidosis during 1999. In the investigation, the effectiveness of various hemopurification modalities on the dialysis-related amyloidosis was ranked as exacerbation, unchanged, or alleviation, so as to analyze the possible relationship between the hemopurification modality and its effectiveness. The analysis was performed using a logistic regression approach, and the results were shown as "the risk of a worse therapeutic ranking" among the hemopurification modalities. The smaller "the risk of a worse therapeutic effect" was, the more effective the treatment modality. When the risk of a worse therapeutic effect for the hemodialysis patients treated by a regular membrane was put at 1.0, the risk for hemodialysis patients using high-flux membrane was 0.489, the off-line hemodiafiltration risk was 0.117, the on-line hemodiafiltration risk was 0.013, and the risk of push/pull hemodiafiltration was 0.017. For hemodialysis with a beta(2)-microglobulin adsorption column, a low risk of 0.054 was found. The results indicated that hemodiafiltration therapy and simultaneous hemodialysis with beta(2)-microglobulin adsorption therapy were more effective treatment for dialysis-related amyloidosis.
authors.affiliation: Patient Registration Committee Headquarters of the Japanese Society for Dialysis Therapy, Tokyo, Japan. s-nakai@mta.biglobe.ne.jp
authors.forename: S
authors.initials: S
authors.lastname: Nakai
authors.forename: K
authors.initials: K
authors.lastname: Iseki
authors.forename: K
authors.initials: K
authors.lastname: Tabei
authors.forename: K
authors.initials: K
authors.lastname: Kubo
authors.forename: I
authors.initials: I
authors.lastname: Masakane
authors.forename: K
authors.initials: K
authors.lastname: Fushimi
authors.forename: K
authors.initials: K
authors.lastname: Kikuchi
authors.forename: T
authors.initials: T
authors.lastname: Shinzato
authors.forename: T
authors.initials: T
authors.lastname: Sanaka
authors.forename: T
authors.initials: T
authors.lastname: Akiba
mesh_terms: D000686:Amyloidosis / Q000453:epidemiology / Q000628:therapy*; D015897:Comorbidity; D003928:Diabetic Nephropathies / Q000453:epidemiology; D005260:Female; D017583:Hemodiafiltration / Q000706:statistics & numerical data*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance; D012042:Registries; D012044:Regression Analysis; D006435:Renal Dialysis / Q000706:statistics & numerical data; D018570:Risk Assessment; D011795:Surveys and Questionnaires; D016896:Treatment Outcome